Fig. 7
Cell migration and proliferation were also regulated by IL-2/sorafenib co-treatment through the JNK-TAZ pathways.a–c Immunofluorescence assay for cell proliferation-related factors. IL-2/sorafenib co-treatment elevated the expression of CDK4 and cyclin D1, which was repressed by SP600125, an inhibitor of the JNK-TAZ pathways.d, e An EdU assay was performed to quantify the cell proliferation. The number of EdU-positive cells was recorded. f–h Cell migration factors such as CXCR4 and CXCR7 were measured via western blotting. *P < 0.05 vs. control group; @P < 0.05 vs. IL-2+ sorafenib group. Cont control